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Abstract:  
Reducing diagnostic delay is key towards decreasing tuberculosis-associated deaths in people living with HIV. 
In tuberculosis patients with retrospective urine testing, the point-of-care Fujifilm SILVAMP TB LAM (FujiLAM) 
could have rapidly diagnosed tuberculosis in up to 89% who died. In FujiLAM negative patients, the probability 
of 12-week survival was 86-97%. 
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Main Text: 
Introduction 
Tuberculosis (TB) is the leading infectious cause of death worldwide and contributed to approximately 300,000 
HIV-related deaths in 2017. Diagnostic delay remains a key factor contributing to mortality in HIV-associated 
TB[1]. Xpert MTB/RIF (Xpert, Cepheid) and Xpert MTB/RIF Ultra are the first-line tests recommended by the 
World Health Organisation (WHO) to diagnose HIV-associated TB. While they provide a sensitive diagnosis, 
they are often unavailable at point-of-care (POC) and patients are not always able to provide sputum[2,3]. The 
urine-based Alere Determine-TB lipoarabinomannan (LAM) assay (AlereLAM, Abbott) was the first POC assay 
for TB and its use has been shown to reduce all-cause mortality in high-risk groups of people living with HIV 
(PLHIV), in two randomized trials[4,5]. Although AlereLAM has been recommended by the WHO in high-risk 
groups, its uptake has been constrained - partially due to limited diagnostic sensitivity. 
 We recently published findings on a next-generation urine LAM assay, Fujifilm SILVAMP TB LAM 
(FujiLAM), demonstrating its superior sensitivity and similar specificity to AlereLAM in hospitalized PLHIV[6]. 
FujiLAM’s high sensitivity is achieved through a pair of high-affinity monoclonal antibodies[7] and a silver 
amplification step. In the identical cohorts presented here, we have also demonstrated that FujiLAM achieves 
good sensitivity for detecting both pulmonary and extra-pulmonary TB[8]. Here we assessed FujiLAM’s ability 
to predict mortality in these two well-characterized cohorts of PLHIV being evaluated for TB and requiring 
hospitalization. 
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Methods 
For this post hoc mortality analysis, we utilized outcome data from two prospective cohorts of the previously 
published diagnostic accuracy study[6]. Both studies enrolled adult (⩾18years) PLHIV requiring hospitalization 
at South African district hospitals, serving communities with a high burden of HIV-associated TB. ‘Cohort-A’ 
consecutively enrolled all consenting PLHIV admitted to the adult medical wards at GF Jooste Hospital, 
irrespective of CD4 count or clinical suspicion of TB, between June 2012 and October 2013[9]. ‘Cohort-B’ 
enrolled hospitalized adult PLHIV at Khayelitsha Hospital with CD4 cell counts≤350 cells/µL in whom TB was 
considered to be the most likely diagnosis, from January 2014 to October 2016[10]. Both cohorts excluded 
those already on TB treatment at the time of admission. The study was approved by the Human Research 
Ethics Committee of the University of Cape Town (UCT). Written informed consent was obtained from 
patients, as per study protocols.   
The demographic and clinical details of patients were recorded at study entry. TB or alternative 
diagnoses were based on a comprehensive laboratory work-up including Xpert and/or mycobacterial culture in 
sputum, blood, urine and other clinically-indicated samples, along with clinical examination and follow-up, as 
previously described[6,9,10] (Supplementary Table 1). FujiLAM and AlereLAM testing was performed on 
thawed, biobanked urine samples at UCT in April 2018[6], according to manufacturer’s instructions. 
‘Microbiologically-confirmed TB’ was defined by the detection of M. tuberculosis in any clinical specimen using 
culture or Xpert. In Cohort-A, ‘clinically-confirmed TB’ was defined as those without a microbiological 
diagnosis of TB, but where the non-study clinical team had started TB treatment based on clinical and/or 
radiological features of TB, as per the primary diagnostic accuracy study[6]. In Cohort-B, ‘clinically-confirmed 
TB’ could not be defined as per the primary diagnostic study[6], as this reference standard incorporated 
survival criteria. Therefore, a composite clinical reference standard was used for ‘clinically-confirmed TB’ in 
Cohort-B that used clinical, radiological, laboratory and treatment data to determine clinical TB diagnoses[10]. 
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AlereLAM and FujiLAM results were not included within the reference standards. ‘TB patients’ refers to those 
with either ‘microbiologically-confirmed TB’ or ‘clinically-confirmed TB’. Analyses that were limited to 
microbiologically-confirmed TB are specified as such. Twelve-week (84-day) outcomes for all patients (alive, 
dead or lost to follow up (LTFU)) were determined from case notes, health record databases, telephone calls 
or personal visits[9,10].  
The proportion of TB patients who died, that could have been rapidly diagnosed by each LAM assay 
with or without the addition of sputum Xpert was calculated. Kaplan-Meier plots were generated to 
investigate the cumulative mortality risk by FujILAM and AlereLAM test result. Negative Predictive Values 
(NPV) for death with Wilson’s 95% confidence intervals were calculated for each LAM assay, by dividing the 
total number of LAM-negative survivors at 12 weeks by the total number of LAM-negative patients. The NPV 
represents the probability that those with a negative LAM result survive 12-weeks. Whether patients were 
treated for TB or any delays in treatment initiation were not factored into outcome analyses. Analysis was 
done using R (version3.6.0). 
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Results  
Overall, 983 patients were included in this analysis: 410 from Cohort-A and 573 from Cohort-B 
(Supplementary Figure 1). The median age of patients in both cohorts was 36, the majority were female and 
nearly half had a prior history of TB (Supplementary Table 2). There were notable differences between 
Cohort-A and -B due to the study eligibility criteria: Cohort-B had lower median CD4 counts, a higher 
proportion of microbiologically-confirmed TB, and features of more advanced illness. 
Amongst TB patients, 18/175 (10.3%) in Cohort-A and 101/496 (20.4%) in Cohort-B died within 12-
weeks. In TB patients who died in Cohort-A, FujiLAM could have diagnosed TB in 88.9% (n=16/18; 95% CI: 
67.2-96.9) versus 66.7% (n=12/18; 95% CI: 43.7-83.7) by AlereLAM (Supplementary Figure 2A). All TB patients 
who died in Cohort-A were also microbiologically-confirmed. Sputum Xpert testing would not have increased 
the diagnostic yield in this group.  
In TB patients who died in Cohort-B, FujiLAM could have rapidly diagnosed TB in 80.2% (n=81/101; 95% 
CI: 71.4-86.8) versus 43.6% (n=44/101; 95% CI: 34.3-53.3) by AlereLAM (Supplementary Figure 2B). The 
combination of FujiLAM and sputum Xpert could have diagnosed 83.2% (n=84/101) of TB patients who died, 
and 96.5% (n=82/85) of microbiologically-confirmed TB patients who died in Cohort-B. The combination of 
AlereLAM and sputum Xpert could have diagnosed 69.3% (n=70/101) of TB patients who died and 80.0% 
(n=68/85) of microbiologically-confirmed TB patients who died, in Cohort-B (Supplementary Figure 2B). 
Kaplan-Meier mortality curves stratified by FujiLAM-status for all patients in Cohort-A and -B, and by 
subgroups, are shown in Figure 1.  In both cohorts, a positive FujiLAM was associated with all-cause mortality 
in the entire cohort up to 12 weeks (Figure 1A and 1B), when limiting to TB patients (Figure 1C and 1D) and 
when limiting to those with CD4 counts≤200cells/µL (independent of TB diagnosis) (Figure 1E and 1F). In 
contrast, an association between AlereLAM result and mortality was only seen in Cohort-A, among all patients 
(Supplementary Figure 3A) and its TB patients (Supplementary Figure 3C).  
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When assessing the NPV of FujiLAM for 12-week mortality, the probability of survival to 12-weeks was 
89.9% (95%CI: 85.7-92.9) in unselected FujiLAM-negative patients from Cohort-A, and 97.0% (95%CI: 89.6-
99.2) in the TB patients of Cohort-A (Supplementary Figure 4). The probability of survival to 12-weeks with a 
negative FujiLAM was 85.8% (95%CI: 80.4-89.9) in all patients from Cohort-B and was 86.2% (95%CI: 79.7-90.9) 
in the TB patients of Cohort-B. Results for AlereLAM, and for both LAM assays in microbiologically-confirmed 
TB are presented in Supplementary Figure 4.  
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Discussion  
In this post hoc analysis of two South African cohorts of hospitalized PLHIV, we found that FujiLAM would have 
rapidly detected TB in up to 89% of patients who died within 3 months. Furthermore, in TB patients, a 
negative FujiLAM result was associated with between 86-97% probability of survival to 3 months.  
AlereLAM-based diagnosis in combination with rapid TB treatment initiation has already been shown 
to reduce mortality in high-risk PLHIV and the association between detection of urinary LAM and mortality is 
not novel[4,5]. However, our findings suggest that the improved sensitivity of FujiLAM to diagnose TB, 
including in less immunocompromised individuals[6], may further increase positive impact on survival by 
enabling rapid, POC diagnosis of TB in a larger proportion of patients. Compared to AlereLAM, FujiLAM 
detected TB in 22-37% more PLHIV who died. FujiLAM shows great promise as an initial TB test allowing for 
rapid treatment initiation in more patients, while drug-susceptibility is confirmed. Those testing FujiLAM-
negative have a reassuring low risk of short-term mortality, with high NPV for death, suggesting less need for 
immediate empiric TB treatment in this group – they should undergo further rapid tests, such as the Xpert, to 
establish an expedited diagnosis in the majority.  
 Strengths of this study include analysis of two well-characterized large cohorts, with low rate of loss-to-
follow-up. With retrospective urine testing, we cannot assess the real-world feasibility of FujiLAM, or whether 
it could have changed TB treatment practices or patient survival.  While the results suggest that there is room 
for benefit due to improved sensitivity, we also recognize the slightly lower specificity noted in our previous 
study with the FujiLAM assay, even though this difference was not statistically significant and might be a result 
of the imperfect reference standard[6]. The risk of treatment based on potentially false-positive results should 
be weighed against the risk of not treating hospitalized PLHIV at high risk of mortality due to TB.  
 Our results suggest that in addition to the superior sensitivity of FujiLAM in comparison to AlereLAM, 
FujiLAM also has greater prognostic value.  The clinical impact, including the potential survival benefit of 
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FujiLAM, should be prospectively assessed in different real-world settings and more diverse populations - 
including outpatients, children and HIV-uninfected patients.  
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Legends: 
Figure 1: Kaplan Meier survival curves by FujiLAM status, up to 12-weeks of follow up. All patients of Cohort-A 
(n=410) (Panel A) and Cohort-B (n=573) (Panel B); TB patients from Cohort-A (n=175) (Panel C), and Cohort-B 
(n=496) (Panel D); Patients with CD4 ≤200 cells/µL, irrespective of TB diagnosis from Cohort-A (n=246) (Panel 
E) and Cohort-B (n=500) (Panel F). p values are based on log-rank test and bands represent 95% confidence 
intervals 
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